Immunogenicity of Reduced-Dose Monovalent Type 2 Oral Poliovirus Vaccine in Mocuba, Mozambique.
1-drop
Mozambique
immunogenicity
monovalent type 2 oral poliovirus vaccine (mOPV2)
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
received:
30
07
2020
accepted:
05
11
2020
pubmed:
13
11
2020
medline:
27
8
2022
entrez:
12
11
2020
Statut:
ppublish
Résumé
The monovalent type 2 oral poliovirus vaccine (mOPV2) stockpile is low. One potential strategy to stretch the existing mOPV2 supply is to administer a reduced dose: 1 drop instead of 2. We conducted a randomized, controlled, open-label, noninferiority trial (10% margin) to compared immunogenicity after administration of 1 versus 2 drops of mOPV2. We enrolled 9-22-month-old infants from Mocuba district of Mozambique. Poliovirus neutralizing antibodies were measured in serum samples collected before and 1 month after mOPV2 administration. Immune response was defined as seroconversion from seronegative (<1:8) at baseline to seropositive (≥1:8) after vaccination or boosting titers by ≥4-fold for those with titers between 1:8 and 1:362 at baseline. The trial was registered at anzctr.org.au (no. ACTRN12619000184178p). We enrolled 378 children, and 262 (69%) completed per-protocol requirements. The immune response of mOPV2 was 53.6% (95% confidence interval, 44.9%-62.1%) and 60.6% (52.2%-68.4%) in 1-drop and 2-drop recipients, respectively. The noninferiority margin of the 10% was not reached (difference, 7.0%; 95% confidence interval, -5.0% to 19.0%). A small loss of immunogenicity of reduced mOPV2 was observed. Although the noninferiority target was not achieved, the Strategic Advisory Group of Experts on Immunization recommended the 1-drop strategy as a dose-sparing measure if mOPV2 supplies deteriorate further.
Sections du résumé
BACKGROUND
The monovalent type 2 oral poliovirus vaccine (mOPV2) stockpile is low. One potential strategy to stretch the existing mOPV2 supply is to administer a reduced dose: 1 drop instead of 2.
METHODS
We conducted a randomized, controlled, open-label, noninferiority trial (10% margin) to compared immunogenicity after administration of 1 versus 2 drops of mOPV2. We enrolled 9-22-month-old infants from Mocuba district of Mozambique. Poliovirus neutralizing antibodies were measured in serum samples collected before and 1 month after mOPV2 administration. Immune response was defined as seroconversion from seronegative (<1:8) at baseline to seropositive (≥1:8) after vaccination or boosting titers by ≥4-fold for those with titers between 1:8 and 1:362 at baseline. The trial was registered at anzctr.org.au (no. ACTRN12619000184178p).
RESULTS
We enrolled 378 children, and 262 (69%) completed per-protocol requirements. The immune response of mOPV2 was 53.6% (95% confidence interval, 44.9%-62.1%) and 60.6% (52.2%-68.4%) in 1-drop and 2-drop recipients, respectively. The noninferiority margin of the 10% was not reached (difference, 7.0%; 95% confidence interval, -5.0% to 19.0%).
CONCLUSION
A small loss of immunogenicity of reduced mOPV2 was observed. Although the noninferiority target was not achieved, the Strategic Advisory Group of Experts on Immunization recommended the 1-drop strategy as a dose-sparing measure if mOPV2 supplies deteriorate further.
Identifiants
pubmed: 33180924
pii: 5979486
doi: 10.1093/infdis/jiaa704
pmc: PMC9400415
doi:
Substances chimiques
Antibodies, Viral
0
Poliovirus Vaccine, Inactivated
0
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-298Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet. 2019 Jul 13;394(10193):148-158
pubmed: 31174831
Science. 2020 Apr 24;368(6489):401-405
pubmed: 32193361
Vaccine. 2018 Mar 20;36(13):1766-1771
pubmed: 29477307
J Infect Dis. 2014 Nov 1;210 Suppl 1:S434-8
pubmed: 25316865
Vaccine. 2015 Jun 4;33(24):2757-63
pubmed: 25917673
N Engl J Med. 2013 Jan 31;368(5):416-24
pubmed: 23363495
Methods Mol Biol. 2016;1387:145-76
pubmed: 26983734
J Infect Dis. 2014 Nov 1;210 Suppl 1:S380-9
pubmed: 25316859
J Infect Dis. 2021 Jan 4;223(1):119-127
pubmed: 32621741